(Q36675139)

15 August 2017

Adalimumab therapy for recalcitrant pyoderma gangrenosum (English)

1 reference

15 August 2017

0 references

Margaret A Fonder

1

1 reference

15 August 2017

Deborah L Cummins

2

1 reference

15 August 2017

Benjamin D Ehst

3

1 reference

15 August 2017

Grant J Anhalt

4

1 reference

15 August 2017

Jon H Meyerle

5

1 reference

15 August 2017

20 November 2006

1 reference

15 August 2017

1 reference

15 August 2017

5

1 reference

15 August 2017

e8

1 reference

Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.

15 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1687150

Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1687150

Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1687150

Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1687150

Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1687150

Anti-TNF-alpha therapies: they are all the same (aren't they?).

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1687150

Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1687150

Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1687150

Management of pyoderma gangrenosum

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1687150

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1687150

Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1687150

Aberrant neutrophil trafficking and metabolic oscillations in severe pyoderma gangrenosum

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1687150

The expression of endothelial leukocyte adhesion molecule-1 (ELAM-1), intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1) in experimental cutaneous inflammation: a comparison of ultraviolet B erythema and delay

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1687150

The treatment of pyoderma gangrenosum using etanercept

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1687150

Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1687150

Pyoderma gangrenosum outside the context of inflammatory bowel disease treated successfully with infliximab

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1687150

Infliximab as a treatment for recalcitrant pyoderma gangrenosum.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1687150

Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1687150

Adalimumab (Humira®) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade®) or etanercept (Enbrel®): results from the STURE registry at Karolinska University Hospital

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1687150

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

4 December 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1687150

Treatment of pyoderma gangrenosum with etanercept

4 December 2018

1 reference

12 December 2020

Anti-tumor necrosis factor alpha monoclonal antibody (infliximab) for the treatment of Pyoderma gangrenosum associated with Crohn's disease

1 reference

12 December 2020

Pyoderma gangrenosum associated with crohn disease: effect of TNF-alpha blockade with infliximab

1 reference

12 December 2020

Favorable response to infliximab treatment in a patient with active Crohn disease and pyoderma gangrenosum

1 reference

12 December 2020

Systemic pyoderma gangrenosum responding to infliximab and adalimumab

1 reference

12 December 2020

Pyoderma gangrenosum treated with anti-TNF alpha therapy (etanercept)

1 reference

12 December 2020

Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab

1 reference

12 December 2020

Interleukin-8 Overexpression Is Present in Pyoderma Gangrenosum Ulcers and Leads to Ulcer Formation in Human Skin Xenografts

1 reference

12 December 2020

Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade

1 reference

12 December 2020

Severe recalcitrant pyoderma gangrenosum treated with infliximab

1 reference

12 December 2020

An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease

1 reference

12 December 2020

Infliximab induces remission of pyoderma gangrenosum

1 reference

12 December 2020

Identifiers

1 reference

15 August 2017

PubMed publication ID

17149453

1 reference